NICE Engagement with Industry Emily Crowe, NICE 6.12.18
Market Access/Orphan Medicines Group
The Market Access Group aims to:
- reduce the hurdles to uptake in the UK and enable innovative products to reach patients in a timely manner
- identify cost-effective solutions to market access challenges
- work with government and officials to communicate solutions to market access challenges
- understand the impact on the varied range of EMIG member companies (biotechs to mature companies) of gaining market access in the UK.
About the Chair
Market Access Group Events
[wcs-schedule id=10]
Downloadable Files:
EMIG Market Access Group 5.9.19
Brexit Opportunities for UK, Angela McFarlane 5.9.19
Developments in Ireland, Brenda Dooley AXIS Consulting 5.9.19
NICE Methodologies & RWD, Steve Norton, Map BioPharma 5.9.19
DATA-CAN, Yosh Cook IQVIA 5.12.19
NHS Commercial Framework, Sovereignty of NHS Data, Angela McFarlane IQVIA 5.12.19